FactaeThe Factual News

Top Stories Focus Media

🌍Monde
France
🏛️Politique
🪖Guerre
🚨Défense & Sécurité

💰Économie
📈Marchés
⚡Énergie
💹Crypto

📱Tech
🤖Intelligence artificielle
💻Informatique
🛡️Cybersécurité

🔬Science
🏥Santé
🌿Écologie

📖Histoire
🏅Sport
🖼️Culture
⚖️Droit
🎓Éducation

Factae

The Factual News

The intelligence of the news. Multi-source, geolocated, synthesized.

Live

Live feed Scoops Immersive map

Explore

Trading Board Trends AI models AI for developers Sources

Information

About Methodology RSS feed Contact Terms Privacy Legal Newsletter

© 2026 Factae. All rights reserved.

Home/📈 marches

📈

Genfit closes steady at 13 euros, awaiting catalysts

Genfit's stock closes at 13 euros on July 16, unchanged from the previous day.

Published 22h·1 source·updated 17h

Lire en français

≈ 15sSpeed

The fact

The biopharmaceutical company remains under investor scrutiny.

Upcoming clinical results could impact the stock's momentum.

🔗Click the link to read an article on the topic:

📈

🧭Explore this topic

📍Paris 📍France 🏢Genfit #genfit #bourse paris #biopharmacie #action #marchés financiers #investisseurs #résultats cliniques

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.→

ParisWorld map →

Follow topic →

Auto-synthesis from 1 media source · identified on July 16, 2026

← Back to home

Discover

Read more

All marches →

Genfit nears key threshold at 13 euros before potential reaction

1sem · 1 source 📈marches

Genfit targets 20 euros after a technical rebound

2sem · 1 source 📈marches

Genfit raises stock target to 15 euros following progress

2sem · 1 source 📈marches

Genfit faces takeover bid as key investment opportunities emerge

6sem · 1 source 📈marches

Genfit: profit-taking after clinical trial results announcement

5sem · 1 source 📈marches40 %

Genfit plummets after clinical trial failure

3sem · 1 source